Narrow Results

The article states a list of some major technology agencies of biotechnology in Shanghai.

Australian Cancer Technology Acquires US Cancer Care Business.

Premier to Accelerate Technology Commercialization Following Trial Success.

Starpharma’s Anti-STDs Lead — VivaGel™ Enters Human Clinical Trial.

Epitan’s Melanotan^® Commences Human Implant Trial.

Sinopharm Group Pharmaceutical Co. Established.

Swedish Company Perbio Science Sets up Headquarters in Hong Kong.

Zydus-Cadila Acquires Alpharma’s French Business.

Virionyx Collaborates with US Organizations to Develop SARS Treatment.

AgResearch To Develop Potential GMO Vaccine for Tuberculosis.

NUS Enterprise Reaps from Horseshoe Crab Research — PryoGene.

The article is about the protective provision in Biotech Strategic Alliances. It is written by three associates/partners at Morgan Lewis. The article is about the strategic partnership between companies and how large and small companies can structure an alliance to protect their investments as well as progress their collaboration.

The article is about Exploit Technologies Pte Ltd that is set up by A*STAR to handle the management and commercialization of the researchers' IP.

ImmunGene Announces Multi-Target R&D Collaboration with Cephalon Australia for Interferon Payload Technology.

Ironwood, Protagonist Collaborate on Peptide Drug Discovery.

First China Pharma Announces Agreement with Medisan.

Vapi Products Industries, Vertellus Form Indian JV to Manufacture and Distribute Specialty Chemicals.

ReproCELL to Enter Collaborative iPS Cell-derived Hepatocytes R&D Agreement with NIBIO.

TriReme Medical Announces Japanese Alliance.

Sime Darby, Mitsui to Collaborate on Bioethanol Plant.

MerLion Signs License Agreement with Alcon to Develop and Commercialize Novel Finafloxacin Otic Product.

PPD Establishes Joint Venture for Drug Discovery of Large Molecules.

Epigenomics and BioChain enter into broad strategic collaboration in China.

China Sunergy's Head of Research wins 2013 ACAA/IELTS Australia China Alumni Awards.

WuXi PharmaTech enters agreement for patient-derived xenograft models with Mayo Clinic's Center for individualized medicine.

Merck enters into further global co-development and commercialization agreement for PARP inhibitor with Chinese R&D company BeiGene.

Creganna-Tactx Medical opens office in China.

Honeywell to modernize petrochemical plants in China.

WuXi PharmaTech to partner with Pharmacyclics.

Novozymes and M&G Chemicals to collaborate on biomass-based plastics in China.

Catalent's Clinical Trial Supply Facility in Shanghai, China opens for business.

Shanghai Institute of Materia Medica and Crown Bioscience to develop mouse clinical center and PDX and Translational Oncology Platform.

Clinical Genomics signs Chinese colorectal screening deal.

WuXi PharmaTech laboratory testing division expands in U.S. with acquisition of XenoBiotic Laboratories.

Roche to invest 450 million Swiss Francs in new diagnostic manufacturing facility in China.

SCYNEXIS, Inc. enters into agreement with Waterstone Pharmaceutical for the development and commercialization of treatment for viral diseases.

Johnson & Johnson Innovation launches Asia Pacific Innovation Center.

ScinoPharm and Nanjing King-friend Biochemical Pharmaceutical team up to jointly enter the Chinese market for new drugs.

Ascletis gains exclusive China market rights from Presidio for clinical stage Hepatitis C virus inhibitor.

Irvine Pharmaceutical Services opens an analytical facility in Hangzhou, China.

Pioneering application of Google Glass by Renji Hospital.

WuXi PharmaTech launches representative office in Israel, forms strategic collaboration with Pontifax.

International Symposium on molecular biology of fruit trees held at Huazhong Agricultural University.

Helsinn Group signs exclusive agreement with Mundipharma for distribution and licensing of netupitant/palonosetron (NEPA) in Brazil.

CrystalGenomics partners with Daewoong Pharmaceutical for Acelex commercialization in Korea.

Roche acquires Signature Diagnostics to advance translational research for next generation sequencing (NGS) diagnostics.

Boehringer Ingelheim renews global technology collaboration agreement with VTU Technology.

Maverix wins $150,000 STTR Award by the National Institute on Drug Abuse for detection of RNA modifications.

Rosetta Genomics receives first patent allowance in Japan.

First-line oral treatment for multiple sclerosis approved in India.

LKCMedicine scientist wins Young Investigator Award at 40th Lorne Conference.

JHL Biotech Opens Innovative Biosimilars Manufacturing Facility in China

Chinese Researchers Find Direct Evidence that Zika Causes Microcephaly in Mice

President Xi Jinping Stresses Science and Technology

Intertek CEO Visits China and Signs Strategic Partnership with CCIC and CQC to Promote Technical Innovation and Quality Assurance

Chinese Academy of Sciences Tops Global Science Institutions

Gene Decides How Young We Look

China Makes Plan to Accelerate Commercialisation of Research Findings

HONG KONG NEWS – Prenetics Launches iGenes Test with Quality HealthCares

HONG KONG NEWS – ORI Healthcare Fund Invests in Pillar Biosciences

Asia's Medical Technology Start-ups Get New Fast Track to Market via Partnership between Cambridge Consultants and Clearbridge Accelerator

Mitsubishi Electric and Sembcorp Industries to Testbed Novel Ozone Backwashing Energy-Saving Membrane Bioreactor

LEO Pharma Enters Biologics through Strategic Partnership with AstraZeneca

Bayer and X-Chem Expand Drug Discovery Collaboration to Discover Novel Medicines

New Gas Chromatography System Brings Power of Orbitrap GC-MS Technology to Routine Applications

A*STAR and MSD Establish a New Research Collaboration to Advance Peptide Therapeutics

Stem Cells Engineered to Grow Cartilage, Fight Inflammation

Mab-Venture Biopharma & Thermo Fisher Establish Asia Pacific’s First “SmartFactory” for Antibody Drugs.

Venus Medtech’s TAVR Device Is Approved By CFDA, Creating A New Era of Interventional Cardiology in China.

Key Diabetes Receptor Structure Determined by International Collaboration.

China Sets Up National Lab Developing Brain-Like AI Technology.

Chinese Scientists Realize On-site Drug Detection.

Scientists Map Single-Copy HIV-1 Provirus Loci in Human Chromosomes in Live Host Cells.

Gene Variant Explains Differences in Blood Fatty Acid Levels.

Scientists Illustrate How Host Cell Responds to Zika Virus Infection.

Hong Kong News – Uni-Bio Science Launches Best-in-Class Oral Anti-Diabetic Drug Mitiglinide Branded “博康泰^®”(Bokangtai).

Innovation and new product development in the biomedical device industry is a complex process requiring interface between medical sciences, precision engineering and information technology. Further challenges are added by the presence of stringent regulatory requirements (e.g. FDA), health economics, outcome considerations, intellectual property issues, and complex nature of market where highly influential intermediaries (medical doctors) not only make product selection for end users (patients) but also contribute to product development. As a result, only a few biomedical device innovations succeed in reaching the market and fewer become commercially successful. A unique characteristic of this industry with regards to innovation and new product development is the importance of research collaboration between the clusters of universities, small and medium sized enterprises (SMEs), hospitals and medical doctors (lead users). The evidence of this is seen in the largest and probably the most established biomedical cluster in San Francisco Bay area, which is home to 31 universities and over 700 life sciences companies [California Healthcare Institute and PricewaterhouseCoopers (2000)]. These clusters of innovation are observed to be contributing significantly to regional economies of the US. Hence many nations as well as biomedical device multinationals are recognizing the importance of these new sources of innovation (i.e. universities, SMEs and users) and their collaboration.

From this angle, the authors in this exploratory study examined biomedical device innovations taking place in select countries in Asia-Pacific and compared that with the innovation output of Singapore from a sample population of 33 000 patented innovations over a four year period (2000–2003). In addition, an attempt was made to understand the factors that are important for successful commercialization of biomedical device innovations from Singapore universities, through a questionnaire based survey of a sample of 50 researchers, and in-depth interviews with a sample of five venture capitalists and five medical doctors (lead users).

The findings based on this study indicate that (1) Singapore university researchers appreciate the need for collaborative research with the industry but are sceptical about the present environment and process in Singapore. (2) Only a third of surveyed researchers have motivation to commercialize their innovations. (3) Medical doctors are more comfortable teaming up with universities than with the industry. (4) Industry has short-term perspective of research collaboration.

The authors' recommendations are to (1) Encourage co-invention teams between universities, industry, and hospitals (medical doctors and clinicians), (2) Build a long-term co-invention culture through collaborative leadership, (3) Attract investment in local biomedical device R&D and production, and (4) Help Singapore universities and researchers appreciate Asia-Pacific market opportunities.

This review paper initially explains that the commercialization of an innovative new technology needs to be underpinned by an appropriate business model. The paper summarizes what has been previously proposed to be the components of a business model and makes the case that an extra one needs to be added and that two of them need interpreting in a special way in order to be appropriate for innovative technology commercialization. It is argued that the decision on what market to target may be crucial to the commercialization process as, often, initial failure may allow no second chances. A way of determining the most appropriate initial market is discussed as this market choice is a determinant of business model choice. Finally, conclusions are drawn on defining and devising business models for commercializing new technologies.

Challenges in innovation processes have influenced the development of agile methods, which are lighter and nimbler tools for development projects. This study elucidates the possibilities of agile methods for enhancing the effectiveness of innovation processes with the aim of quickly and successfully commercializing new technology. The focus is on different process phases of commercialization, from identifying the business potential to finalizing the innovation commercialization plan. As a result of the study, a novel, rapid, and agile process was created to improve the effectiveness of the technology-based innovation process, supporting the creation of more sustainable and valuable business models.

Previous studies have been silent on how institutional factors influence scientists’ entrepreneurial cognitions and behavior. Transition economies offer a unique opportunity for addressing this issue since different generations of scientists experienced vastly different ideology and management systems. Built on the entrepreneurial cognitions and contextualization views and interview data from scientists in Vietnam, this study found that scientists internalized institutional factors to form their motivations, partnership approaches, and behavioral competencies, which in turn influence their chosen modes of entrepreneurship. This suggests that new institutions which address younger generations and focus on developing entrepreneurial qualities are pertinent to promote commercialization in transition economies.

This paper identifies differences in institutional contexts (legislation) between Sweden and the UK and their effects on technology transfer policies. It then proceeds to examine how such activities are organized by universities. Empirical evidence from surveys conducted with technology transfer managers at eight Swedish universities and eleven UK universities gathered in Sweden and the UK during 2004 is analyzed. It is argued that the historical developments of these systems depend on different institutional contexts, which influence the modes of organization. The UK technology transfer system is based on similar legislation to that of the US, with IPRs being granted to the universities. The Swedish system, however, grants IPRs to the individual researchers, though with some new features — such as science parks and incubators — suggesting a change towards greater agent (university) involvement in encouraging technology transfer. This change indicates a breakthrough for the "entrepreneurial university" in Sweden.

Science-based innovation emerged from novel and discontinuous innovations which provoked irreversible yet significant changes in science and technology. This research investigated the commercialization process of artemisinin, a typical science-based innovation in China. Due to her research involvement with artimisinin (qinghaosu), Tu Youyou received the 2011 Lasker Award in clinical medicine and the 2015 Nobel Prize in Physiology or Medicine jointly with William C. Campbell and Satoshi Ōmura. In this paper, the authors reviewed the process of artemisinin’s innovation from labs in a research institute to its entrance into the market. Based on the research, we reached the following conclusions. First, during the process of science-based innovation, a “new technology platform” might be established and a series of applications might be invented. Second, the extensive cooperation among research institutions and companies played a vital role in the science-based innovation. Third, the science-based innovation emerged through multidisciplinary research teams as well as contacts among scientists with cross-fields expertise. Fourth, for science-based innovation, early research funding mainly relied on public funds. During the commercialization stage, corporate funding plays a major role. Fifth, a clear research objective, an overall planning, coordination, and the stability of policies were also important factors in the entire science-based innovation process.

Science empowers as a nation’s toughest weapon in the future global competition and cooperation. A large number of countries listed in-house R&D for science-based innovations as their core development strategy in the next decade. This paper conducts multi-case analysis on four science-based innovations in China as a reference for how a new science-based venture superseded in global market and developed indigenous capability to generate much business value as well as scientific value. The four cases detailed are container inspection system, hot redundant JX-100 DCS, high-performance Dawning supercomputers and Chinese-character laser phototypesetting system. We concluded that the successful commercialization of a nationwide and grand scientific project requires the following: (1) visionary scientists’ solid authority, direct participation, business acumen and a strong sense of patriotism, without intermediaries, are the core for successful science-based innovation and commercialization during knowledge transformation; and (2) the powerful and direct support from the policymakers. Forms of support may vary from financial incentives, policy enforcement and endorsement. The consequences for the success of science-based innovations are the creation of highly-skilled manpower, new market as well as shifting away from low-cost strategy to innovative strategy.

This paper identifies differences in institutional contexts (legislation) between Sweden and the UK and their effects on technology transfer policies. It then proceeds to examine how such activities are organized by universities. Empirical evidence from surveys conducted with technology transfer managers at eight Swedish universities and eleven UK universities gathered in Sweden and the UK during 2004 is analyzed. It is argued that the historical developments of these systems depend on different institutional contexts, which influence the modes of organization. The UK technology transfer system is based on similar legislation to that of the US, with IPRs being granted to the universities. The Swedish system, however, grants IPRs to the individual researchers, though with some new features —such as science parks and incubators — suggesting a change towards greater agent (university) involvement in encouraging technology transfer. This change indicates a breakthrough for the “entrepreneurial university” in Sweden.

Tissue engineering can be broadly defined as the combination of biology and engineering to repair or replace lost tissue function. From an industry perspective, the field encompasses implanted biomaterials, cell and tissue transplants and therapies, and even extracorporeal cellular devices. To achieve its goals, tissue engineering must effectively utilize not only multiple aspects of engineering but also several aspects of biology that govern mechanisms of organ development, repair and regeneration. The field has always had a strong focus on application yet the challenge of integrating biological science, engineering and medicine has kept many past efforts from reaching their therapeutic and commercial potential. This chapter covers the evolution of tissue engineering, looking at the change in emphasis from bioengineering to stem cell biology and the potential impact of this shift in focus from an industrial perspective. In addition, we have analyzed four major commercial thrusts from past to present: vascular tissue engineering, cartilage repair, liver-assist devices and skin constructs, paying particular attention to how the biomedical disciplines must be integrated to achieve commercial feasibility and therapeutic success. Each example yields one or more important and practical lessons learnt that could be instructive for most future medical and commercial efforts in tissue engineering.